In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 1, 2001, Pages 280-290

  Bundschuh, D S ^a   Eltze, M ^a   Barsig, J ^a   Wollin, L ^a   Hatzelmann, A ^a   Beume, R ^a  

^a Byk Gulden ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYCLOPROPYLMETHOXY 4 DIFLUOROMETHOXY N [3,5 DICHLOROPYRID 4 YL] BENZAMIDE; BENZAMIDE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROFLUMILAST; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GUINEA PIG; HELPER CELL; IMMUNOMODULATION; INFLAMMATORY CELL; LUNG LAVAGE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT DISEASE; T LYMPHOCYTE ACTIVATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ANTI-ASTHMATIC AGENTS; BENZAMIDES; BRONCHOCONSTRICTION; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; LIPOPOLYSACCHARIDES; LUNG DISEASES, OBSTRUCTIVE; MALE; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; TRACHEA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035078823     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mechanics of respiration in unanesthetized guinea pigs
2. Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
3. An in vivo model for measuring antigen-induced SRS-A-mediated bronchoconstriction and plasma SRS-A levels in the guinea pig
4. Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs
5. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-cyclopentyloxy-4-methoxybenzamides and analogues
6. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992
7. Therapeutic strategies for allergic diseases
8. Chronic obstructive pulmonary disease
9. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
10. T cells and eosinophils in the pathogenesis of asthma
11. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors
12. Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized Brown-Norway rats
13. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
14. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression
15. Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice
16. In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-α by PDE inhibitors
17. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function
18. Phosphodiesterase 4 inhibitors and the treatment of asthma-where are we now and where do we go from here?
19. SB 207499, a second generation phosphodiesterase 4 inhibitor, reduces TNFα and interleukin-4 production in vivo
20. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo
21. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects
22. Automatic leukocyte differentiation in bronchoalveolar lavage fluids of guinea pigs and Brown-Norway rats
23. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
24. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions
25. RP 73401 (a phosphodiesterase IV inhibitor) single dose does not prevent allergen induced broncho-constriction during the early phase reaction in asthmatics
26. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease and asthma
27. TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation
28. Therapeutic potential and strategies inhibiting tumor necrosis factor-alpha
29. The many faces of airway inflammation - Asthma and chronic obstructive pulmonary disease
30. Anti-inflammatory and bronchodilator properties of RP73401, a novel and selective phosphodiesterase type IV inhibitor
31. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways
32. Kinetics and quantitation of eosinophil and neutrophil recruitment to allergic lung inflammation in a Brown Norway rat model
33. Therapeutic potential of selective PDE inhibitors in asthma
34. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai
35. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram
36. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages
37. Phosphodiesterase isoenzymes - Molecular targets for novel anti-asthma agents
38. Phosphodiesterases the journey towards therapeutics
39. Effect of removal of epithelium on antigen-induced smooth muscle contraction and mediator release from guinea pig isolated trachea
40. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig
41. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram
42. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma
43. Results of a phase II study of the antidepressant effect of rolipram